5-(Azepan-1-ylsulfonyl)isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-(Azepan-1-ylsulfonyl)isoquinoline
• 化学式: C₁₅H₁₈N₂O₂S
• 分子量: 290.4
• InChiKey: XYCKMPQJHRSHDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  58.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Heterocyclic N-Oxides as Hypoxic Selective Protein Kinase Inhibitors
  申请人：Boyle Robert George

  公开号：US20100048540A1

  公开（公告）日：2010-02-25

  The invention relates to novel heterocyclic N-oxides which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted ahgiogenesis and/or cellular proliferation by administering effective amounts of such compounds.
• PROPHYLACTIC OR THERAPEUTIC AGENT FOR AXIAL MYOPIA
  申请人：Ikuno Yasushi

  公开号：US20110130388A1

  公开（公告）日：2011-06-02

  Since high myopia increases the risks of retinal detachment, myopic chorioretinal atrophy, myopic choroidal neovascularization, glaucoma, and cataract, establishment of prophylaxis against the progress of myopia is desired. However, at present, there is no effective prophylaxis or therapy for axial myopia, which is considered to cause high myopia. The present invention, which was completed based on the finding that Rho kinase inhibitors have an inhibitory action on axial length extension, provides a prominently effective prophylactic or therapeutic agent comprising a Rho kinase inhibitor as an active ingredient for axial myopia.
• PHARMACOLOGICAL TARGETING OF VASCULAR MALFORMATIONS
  申请人：Li Dean

  公开号：US20110112053A1

  公开（公告）日：2011-05-12

  Disclosed herein are compositions and methods for decreasing vascular permeability in a blood vessel and treating or preventing conditions associated with defects or injuries of vascular endothelium. For example, the disclosed compositions and methods can be used to treat a vascular dysplasia such as cerebral cavernous malformation (CCM). These methods relate generally to the use of compositions that inhibit RhoA GTPase levels or activity, such as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.
• METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
  申请人：Whalen Anne

  公开号：US20110224128A1

  公开（公告）日：2011-09-15

  The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.
• LOCAL TREATMENT OF NEUROFIBROMAS
  申请人：CHEN Ruihong

  公开号：US20120315298A1

  公开（公告）日：2012-12-13

  A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed.